The article is a fair to poor assessment of CytoDyn's catalysts and state of affairs. The author needs to do his DD. There are many goals that might very well be achieved by 2022 that are not listed.
Who cares about the lies and nonsense that the shorts utter? I dismiss them out of hand.
"Overall, my bull thesis remains intact and I am still keeping to my “ditch list” of CytoDyn receiving FDA approval for Leronlimab in HIV in combination with HAART, and the company begins the process of uplisting to a major exchange by the end of 2021. If the company fails to complete both of those objectives by the beginning of 2022, I will liquidate the rest of my position until the company is able to address these concerns."
What a brainless statement. The author plans to ditch the stock, jump ship under the above conditions. Like he has the foresight to know what CytoDyn's situation will be at the beginning of 2022.
"I have been sitting on hands my over the past several months after banking some profits. However, I am contemplating on adding to my position in the coming weeks in anticipation the company will be firing out press releases like a Gatling Gun, so any positive news could catch some shorts off-guard."
The shorts might not be the only ones caught off-guard. Anyone not in the stock now could miss out on any number of imminent catalysts.
Nothing personal, Saltzy. I just find the article to be amateurish.
News 
Market Data 
Discover 
